ALK-IN-1 (Brigatinib analog, AP26113 analog)
Important Notice: For research use only. We do not sell to patients.
Not your Region? View all Distributors
Important Notice: For research use only. We do not sell to patients.
Not your Region? View all Distributors
Discription | AP26113 is an orally-available, potent, and selective inhibitor of ALK with a potency of 0.62 nM against wild-type and activity against a wide range of mutants, including the crizotinib-resistant L1196M line. In a panel of EML4-ALK or NPM-ALK-positive cell lines, AP26113 has IC50 values of 4-31 nM. [1][2] AP26113 is effective against sensitive and resistant H3122 cells, reducing cell growth, suppressing ALK phosphorylation, and inducing apoptosis. In Ba/F3 cells expressing native or mutant EML4-ALK, AP26113 was active at IC50s of 10 and 24 nM, respectively. [3] | ||
---|---|---|---|
Targets |
|
Catalog Num | A11948 |
---|---|
Formula | C26H34ClN6O2P |
Molecular Weight | 529.01 |
CAS Number | 1197958-12-5 |
SMILES | CN(C)C1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)NC4=CC=CC=C4P(=O)(C)C)Cl)OC |
Synonyms | AP-26113 |
Storage | Store lyophilized at -20ºC, keep desiccated. |
In vitro (25°C) | DMSO | 40 mg/mL (75.61 mM) | |
Water | Insoluble | ||
Ethanol | 93 mg/mL (175.8 mM) | ||
In vivo | NMP+PEG300 (10+90, v+v) | 28 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 18.9 mL | 94.52 mL | 189.03 mL |
0.5 mM | 3.78 mL | 18.9 mL | 37.81 mL |
1 mM | 1.89 mL | 9.45 mL | 18.9 mL |
5 mM | 0.38 mL | 1.89 mL | 3.78 mL |
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2